The following first ran on CounterPunch at the height of the COVID pandemic in January of 2022. Are anti-vaccine ...

It can happen even after a mild case and at any age, although rates have declined since the pandemic’s early years. Studies show vaccination can lower the risk. It also is not clear what causes long ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

The support is designed to speed development of well-matched H5N1 vaccines and pave the way for vaccines against other ...

In this study, the authors estimated that Paxlovid reduced the risk of hospitalization by 39% (95% confidence interval [CI], ...

The Department of Health Services has awarded $590 million to Moderna to speed up the development of flu vaccines, including ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

Shares of Moderna Inc. fell sharply on Monday after the biotech firm projected a steep decline in 2025 revenues, falling below Wall Street expectations. The company, known for its COVID-19 vaccine ...